Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Mar 18;86(5):2379-2381.
doi: 10.1097/MS9.0000000000001888. eCollection 2024 May.

Revumenib (SNDX-5613): a promising menin inhibitor for the management of relapsed and refractory acute myeloid leukaemia (AML)

Harmla Hussain  1 , Syeda Mahrukh Fatima Zaidi  1 , Syed Mohammad Hasan  1 , Aelia Sarv Jahan  1 , Burhanuddin Sohail Rangwala  2 , Hussain Sohail Rangwala  2 , Mirha Ali  2 , Asma Ahmed Farah  3
Affiliations
Editorial

Revumenib (SNDX-5613): a promising menin inhibitor for the management of relapsed and refractory acute myeloid leukaemia (AML)

Harmla Hussain et al. Ann Med Surg (Lond). .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no potential conflicts of interest concerning the research, authorship, and/or publication of this article.Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.

References

    1. Siegel RL, Miller KD, Wagle NS, et al. . Cancer statistics, 2023. CA Cancer J Clin 2023;73:17–48. - PubMed
    1. Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia. Blood 2016;127:53–61. - PMC - PubMed
    1. Shahar E, Folsom a R, Melnick SL, et al. . The New England Journal of Medicine Downloaded from nejm.org at Pfizer Japan Inc. on February 17, 2013. For personal use only. No other uses without permission. Copyright © 1994 Massachusetts Medical Society. All rights reserved. N Engl J Med 1994;331:228–233. - PubMed
    1. Issa GC, Aldoss I, DiPersio J, et al. . The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature 2023;615:920–924. - PMC - PubMed
    1. Katona BW, Glynn RA, Hojnacki TA, et al. . Menin: expanding and dichotomous roles in cancer. Oncoscience 2019;6:368–370. - PMC - PubMed

Publication types